Abstract
Valproic acid (VPA) has been reported as inhibitor of histone deacetylases (HDACs). Several reports indicated that HDACs play a crucial role in the pathogenesis of fibrosis and hepatic stellate cell (HSC) activation. The present study was aimed to evaluate the anti-fibrotic effect of VPA against thioacetamide (TAA)-i7nduced hepatic fibrosis and activation of the HSC in rat. VPA and TAA were administrated intraperitoneally at the dose of 400 and 200 mg/kg each at 2 days interval, respectively for a period of 6 weeks. Administration of TAA significantly increased the absolute and relative liver weight, aspartate aminotransferase and alanine aminotransferase levels, which were significantly decreased by VPA treatment as compared to TAA control. VPA treatment prevents the TAA-induced activation of HSC and decreases collagen deposition and infiltration of inflammatory cells as revealed by Sirius red and H&E staining. Interestingly, VPA co-treatment led to significantly increase the DNA damage and apoptosis in the activated HSC as compared to TAA control. Further, TAA decreased the expression of matrix metalloproteinase-2 (MMP-2), while VPA co-treatment significantly increased the expression of MMP-2 as compared to respective control. The present study clearly demonstrated that VPA treatment significantly alleviates TAA-induced activation of HSC and subsequent hepatic fibrosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 44-55 |
| Number of pages | 12 |
| Journal | Human and Experimental Toxicology |
| Volume | 34 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 23 2015 |
| Externally published | Yes |
Keywords
- HDAC inhibitor
- hepatic fibrosis
- Hepatic stellate cell
- thioacetamide
- valproic acid
ASJC Scopus subject areas
- Toxicology
- Health, Toxicology and Mutagenesis